The WACC of Pharbaco Central Pharmaceutical No1 JSC (PBC.VN) is 6.9%.
| Range | Selected | |
| Cost of equity | 8.90% - 13.30% | 11.10% |
| Tax rate | 22.20% - 22.70% | 22.45% |
| Cost of debt | 4.00% - 8.00% | 6.00% |
| WACC | 5.1% - 8.6% | 6.9% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.65 | 0.91 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.90% | 13.30% |
| Tax rate | 22.20% | 22.70% |
| Debt/Equity ratio | 1.94 | 1.94 |
| Cost of debt | 4.00% | 8.00% |
| After-tax WACC | 5.1% | 8.6% |
| Selected WACC | 6.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for PBC.VN:
cost_of_equity (11.10%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.65) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.